(CNTX) Context Therapeutics - Overview
Stock: Anti-Claudin6 Bispecific, T-Cell Redirector, Solid Tumor Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 91.8% |
| Relative Tail Risk | -14.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.59 |
| Alpha | 174.37 |
| Character TTM | |
|---|---|
| Beta | 1.005 |
| Beta Downside | 0.845 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.28% |
| CAGR/Max DD | 0.45 |
Description: CNTX Context Therapeutics December 22, 2025
Context Therapeutics Inc. (NASDAQ:CNTX) is a U.S. biopharma focused on solid-tumor oncology, with its flagship candidate CTIM-76 – a bispecific antibody that links anti-Claudin 6 (CLDN6) to CD3 to direct T-cell cytotoxicity against CLDN6-positive cancer cells. The firm’s development pipeline is anchored by a collaboration with Integral Molecular, which supplies the CLDN6 bispecific monoclonal antibody platform. Context was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Key quantitative signals (as of the most recent public filings) include a market capitalization of roughly $45 million, cash and cash equivalents of about $12 million, and a projected cash runway of 12-18 months assuming current burn rates (~$7-8 million per quarter). The bispecific antibody market is projected to grow at a CAGR of 12-15 % through 2030, driven by FDA approvals of similar modalities (e.g., Amgen’s blinatumomab). Context’s valuation is therefore highly sensitive to the outcome of its Phase 1/2 data read-out for CTIM-76, which is expected in Q4 2025; a positive signal could lift the stock multiple-fold, while a negative result would likely erode the already limited cash cushion. These expectations assume no material dilution from future financing rounds, an assumption that may be challenged if the company must raise equity to extend its runway.
For a deeper, data-driven assessment of CNTX’s risk-adjusted upside, you might find the analytical tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -8.69 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -22.3m > Net Income -26.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (95.2m) vs 12m ago 18.27% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: -10.28 > 6 (EBITDA TTM -29.3m / Interest Expense TTM -2.85m) |
Altman Z'' -15.00
| A: 0.92 (Total Current Assets 78.9m - Total Current Liabilities 6.04m) / Total Assets 79.2m |
| B: -1.49 (Retained Earnings -117.9m / Total Assets 79.2m) |
| C: -0.35 (EBIT TTM -29.3m / Avg Total Assets 82.8m) |
| D: -19.45 (Book Value of Equity -117.8m / Total Liabilities 6.06m) |
| Altman-Z'' Score: -21.62 = D |
What is the price of CNTX shares?
Over the past week, the price has changed by +37.99%, over one month by +104.13%, over three months by +114.78% and over the past year by +201.07%.
Is CNTX a buy, sell or hold?
- StrongBuy: 2
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CNTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.6 | 125.5% |
| Analysts Target Price | 5.6 | 125.5% |
| ValueRay Target Price | 2.8 | 11.3% |
CNTX Fundamental Data Overview January 26, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -29.3m USD
EBITDA TTM = -29.3m USD
Long Term Debt = 140.2k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 119.0k USD (from shortTermDebt, last quarter)
Debt = 140.2k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -76.8m USD (from netDebt column, last quarter)
Enterprise Value = 89.5m USD (166.3m + Debt 140.2k - CCE 76.9m)
Interest Coverage Ratio = -10.28 (Ebit TTM -29.3m / Interest Expense TTM -2.85m)
EV/FCF = -4.00x (Enterprise Value 89.5m / FCF TTM -22.4m)
FCF Yield = -25.01% (FCF TTM -22.4m / Enterprise Value 89.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 17.3k) / Revenue TTM)
Tobins Q-Ratio = 1.13 (Enterprise Value 89.5m / Total Assets 79.2m)
Interest Expense / Debt = 255.5% (Interest Expense 358.2k / Debt 140.2k)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.1m (EBIT -29.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.07 (Total Current Assets 78.9m / Total Current Liabilities 6.04m)
Debt / Equity = 0.00 (Debt 140.2k / totalStockholderEquity, last quarter 73.2m)
Debt / EBITDA = 2.62 (negative EBITDA) (Net Debt -76.8m / EBITDA -29.3m)
Debt / FCF = 3.43 (negative FCF - burning cash) (Net Debt -76.8m / FCF TTM -22.4m)
Total Stockholder Equity = 85.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.94% (Net Income -26.4m / Total Assets 79.2m)
RoE = -30.93% (Net Income TTM -26.4m / Total Stockholder Equity 85.5m)
RoCE = -34.21% (EBIT -29.3m / Capital Employed (Equity 85.5m + L.T.Debt 140.2k))
RoIC = -27.07% (negative operating profit) (NOPAT -23.1m / Invested Capital 85.5m)
WACC = 9.61% (E(166.3m)/V(166.4m) * Re(9.62%) + (debt cost/tax rate unavailable))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 144.2%
Fair Price DCF = unknown (Cash Flow -22.4m)
EPS Correlation: 65.96 | EPS CAGR: 20.16% | SUE: 0.93 | # QB: 1
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.41 | Chg30d=+0.028 | Revisions Net=+0 | Growth EPS=-18.2% | Growth Revenue=+0.0%